Authors:
Porter, DL
Thompson, DR
Alper, W
Romeiser, R
Citation: Dl. Porter et al., Remotely sensed ocean observations of the Coastal Mixing and Optics site from synthetic aperture radars and advanced very high resolution radiometers, J GEO RES-O, 106(C5), 2001, pp. 9623-9638
Citation: Dl. Porter, The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation, J HEMATH ST, 10(4), 2001, pp. 465-480
Authors:
Porter, DL
Luger, SM
Duffy, KM
Stadtmauer, EA
Laport, G
Schuster, SJ
Orloff, G
Tsai, D
McDaid, K
Kathakali, A
Leonard, DGB
Antin, JH
Citation: Dl. Porter et al., Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation, BIOL BLOOD, 7(4), 2001, pp. 230-238
Citation: Ar. Wakoff et Dl. Porter, The biology and treatment of chronic myelogenous leukemia - The Brunstein/McGlave article reviewed, ONCOLOGY-NY, 15(1), 2001, pp. 31-32
Authors:
Tsai, DE
Hardy, CL
Tomaszewski, JE
Kotloff, RM
Oltoff, KM
Somer, BG
Schuster, SJ
Porter, DL
Montone, KT
Stadtmauer, EA
Citation: De. Tsai et al., Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients, TRANSPLANT, 71(8), 2001, pp. 1076-1088
Authors:
Vasconcelles, MJ
Jiang, YD
McDaid, K
Gilooly, L
Wretzel, S
Porter, DL
Martin, CE
Goldberg, MA
Citation: Mj. Vasconcelles et al., Identification and characterization of a low oxygen response element involved in the hypoxic induction of a family of Saccharomyces cerevisiae genes - Implications for the conservation of oxygen sensing in eukaryotes, J BIOL CHEM, 276(17), 2001, pp. 14374-14384
Authors:
Sikora, TD
Porter, DL
Babin, SM
Wisecup, MD
Citation: Td. Sikora et al., Observations of a progressive warm-fresh oceanic front and a cool-moist atmospheric front at Duck, North Carolina, BOUND-LAY M, 100(2), 2001, pp. 349-361
Authors:
Mathias, C
Mick, R
Grupp, S
Duffy, K
Harris, F
Laport, G
Stadtmauer, E
Luger, S
Schuster, S
Wasik, MA
Porter, DL
Citation: C. Mathias et al., Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation, J HEMATH ST, 9(3), 2000, pp. 393-400
Authors:
Visonneau, S
Cesano, A
Porter, DL
Luger, SL
Schuchter, L
Kamoun, M
Torosian, MH
Duffy, K
Sickles, C
Stadtmauer, EA
Santoli, D
Citation: S. Visonneau et al., Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer, CLIN CANC R, 6(5), 2000, pp. 1744-1754
Authors:
Porter, DL
Collins, RH
Hardy, C
Kernan, NA
Drobyski, WR
Giralt, S
Flowers, MED
Casper, J
Leahey, A
Parker, P
Mick, R
Bate-Boyle, B
King, R
Antin, JH
Citation: Dl. Porter et al., Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions, BLOOD, 95(4), 2000, pp. 1214-1221
Authors:
Stadtmauer, EA
Tsai, DE
Sickles, CJ
Mick, R
Luger, SM
Porter, DL
Mangan, PA
Schuchter, LM
Schuster, SJ
Loh, EY
Magee, DA
Sachs, RA
Wall, ME
Moore, J
Buzby, GP
Zaleta, E
Kamoun, M
Silberstein, LE
Citation: Ea. Stadtmauer et al., Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination, MED ONCOL, 16(4), 1999, pp. 279-288
Authors:
Moore, HCF
Mick, R
Solin, LJ
Sickles, C
Mangan, PA
Luger, SM
Fox, KR
Schuchter, LM
Loh, E
Porter, DL
Schuster, S
Buzby, GP
Glatstein, E
Silberstein, LE
Stadtmauer, EA
Citation: Hcf. Moore et al., Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: Impact on the delivery of local-regional radiation therapy, ANN ONCOL, 10(8), 1999, pp. 929-936
Authors:
Porter, DL
Connors, JM
Van Deerlin, VMD
Duffy, KM
McGarigle, C
Saidman, SL
Leonard, DGB
Antin, JH
Citation: Dl. Porter et al., Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies, J CL ONCOL, 17(4), 1999, pp. 1234-1243
Authors:
Tsai, DE
Moore, HCF
Hardy, CL
Porter, DL
Loh, EY
Vaughn, DJ
Luger, S
Schuster, SJ
Stadtmauer, EA
Citation: De. Tsai et al., Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation, BONE MAR TR, 24(5), 1999, pp. 521-526